Subsidiary gets tax order disallowing Rs 53.37 cr losses

Regulatory & Legal View source PDF Explain this filing

JUBLPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.3%Reaction day

₹975.45

prior close

₹976.00

announcement price

After-mkt

timing

Nifty Smallcap 250market+0.5%-0.2% vs market

Pharmaceuticals peers, median of 165sector-0.0%+0.3% vs sector

On the reaction day the stock moved 0.2 pts less than Nifty Smallcap 250 and 0.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.8

10m

+0.6

15m

+0.5

30m

+0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.3+0.5-0.2-0.0+0.3

Next day

-0.3+1.5-1.8+0.1-0.4

-0.6+1.6-2.1+0.5-1.1

+0.8+2.0-1.2+0.1+0.8

+0.6+1.3-0.7-0.4+1.0

-0.3-0.7+0.4-1.2+0.9

-0.6+2.2-2.8+0.0-0.6

15d

+1.5+0.8+0.7-1.4+2.9

-4.2+2.5-6.7-1.1-3.1

-7.5+3.6-11.2+1.0-8.5

+2.5-0.7+3.3+0.0+2.5

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Jubilant Biosys, a wholly-owned subsidiary of Jubilant Pharmova, received a rectification order from the Noida Income Tax Assessing Officer for Assessment Year 2019-20 (FY 2018-19) disallowing brought forward losses of Rs 53.37 crores. The company will appeal before the National Faceless Appeal Centre (NFAC) and expects to get relief, with no material adverse financial impact anticipated.

Likely market impact

Potential tax exposure of about Rs 53.37 cr; company plans appeal and expects relief, so near-term financial impact likely limited.